📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-06 16:17
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
4 announcements match the current filters (relevance ≥ 5).
Chandra Bhagat Pharma to issue 66 lakh warrants; proposes 76% hike in authorized capital
Chandra Bhagat Pharma has convened its 23rd AGM for September 1, 2026, to approve a major capital restructuring. The company proposes increasing its authorized share capital from ₹8.5 crore to ₹15 crore to facilitate growth. Most significantly, it seeks approval to issue up to 66,00,000 convertible warrants on a preferential basis to both promoters and non-promoters. Given the company's small market capitalization of ₹30 crore, this fundraise is highly material and suggests a significant upcoming capital infusion.
Confidence: HIGH
What changedThe company is transitioning from a restricted capital structure to a more flexible one by nearly doubling its authorized capital and initiating a large-scale preferential fundraise.
Why it mattersFor a micro-cap company with a ₹30 crore market cap, issuing 66 lakh warrants (potentially representing over 80% of existing equity) is a transformative event that could provide the necessary liquidity for expansion or deleveraging.
Proposed Warrants: 66,00,000 unitsAuthorized Capital Increase: ₹8.5 Cr to ₹15.0 CrFY26 Export Earnings: ₹80.24 CrMarket Cap: ₹30 CrDebt to Equity: 0.50
📅 Short termThe announcement of promoter participation in the warrant issue is likely to be viewed positively by the market in the coming weeks, though the scale of potential dilution may cause some volatility.
📈 Long termIf the capital raised is deployed into high-margin pharmaceutical segments, it could structurally re-rate the company from its current low P/E of 7.6. However, long-term value depends entirely on the execution of the projects funded by this capital.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Substantial equity dilution
- SME platform liquidity risks
- Pricing of warrants not yet finalized in the notice
Key Highlights
Proposed issuance of up to 66,00,000 convertible warrants to promoters and non-promoters on a preferential basis
Increase in Authorized Share Capital by 76.5% from ₹8.5 crore to ₹15 crore
Reported FY26 export earnings (FOB value) of ₹80.24 crore, up from ₹69.58 crore in FY25
Promoter holding remains strong at 73.02% as of March 2026
Annual General Meeting scheduled for September 1, 2026, to vote on these resolutions
👀 What to Watch
Investors should monitor the upcoming AGM results for the approval of warrant issuance and specifically look for the 'Issue Price' of these warrants. The utilization of these funds—whether for debt reduction (currently ₹17 Cr) or capacity expansion—will be the primary driver for the stock.
Chandra Bhagat Pharma to issue 66 lakh warrants; Authorized Capital to reach ₹15 Cr
Chandra Bhagat Pharma has announced its FY26 Annual Report and a notice for its 23rd AGM on September 1, 2026. The company proposes to increase its authorized share capital from ₹8.5 crore to ₹15 crore, a 76% increase. Most significantly, it seeks approval to issue up to 66,00,000 convertible warrants on a preferential basis to promoters and non-promoters. This potential fundraise is substantial relative to its current ₹30 crore market cap. Operationally, the company reported a 15% growth in export earnings to ₹80.24 crore for FY26.
Confidence: HIGH
What changedThe company is transitioning from a routine reporting cycle to a significant capital-raising phase through the issuance of 66 lakh warrants and a major expansion of its authorized capital base.
Why it mattersFor a micro-cap company with a ₹30 crore valuation, a 66-lakh warrant issue is highly material and could significantly dilute existing equity while providing the necessary capital to scale its low-margin pharmaceutical trading/manufacturing operations.
Proposed Warrants: 66,00,000 unitsAuthorized Capital Increase: ₹6.50 CrFY26 Export Revenue: ₹80.24 CrFY26 Total Revenue: ₹116.0 CrCurrent Market Cap: ₹30 Cr
📅 Short termThe market is likely to react positively to the fundraise proposal and the continued increase in promoter stake, though the exact warrant pricing will be the key driver.
📈 Long termThe long-term trajectory depends on the company's ability to improve its thin operating margins (1.5%) using the fresh capital and sustaining the 15% export growth rate.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution from warrant conversion
- Very low operating profit margins (1.5%)
- High dependence on export realizations
Key Highlights
Proposed issuance of up to 66,00,000 convertible warrants on a preferential basis to promoters and non-promoters
Increase in Authorized Share Capital by ₹6.50 crore to a new total of ₹15.00 crore
FY26 Export earnings (FOB) grew to ₹80.24 crore compared to ₹69.59 crore in FY25
Promoter holding has increased from 69.29% in Sep 2024 to 73.02% as of Mar 2026
Annual General Meeting (AGM) scheduled for September 1, 2026, to vote on these capital measures
👀 What to Watch
Investors should monitor the AGM outcome on September 1, 2026, specifically the pricing of the warrants and the specific identity of the non-promoter allottees to gauge the quality of new capital.
₹29.04 Cr Fundraise via Preferential Issue of 66 Lakh Convertible Warrants at ₹44/share
Chandra Bhagat Pharma's board has approved a preferential issue of 66 lakh convertible warrants to raise ₹29.04 crore. The issue price of ₹44 per warrant represents a premium of approximately 11.6% over the current market price of ₹39.4. Promoters and promoter group members are the primary subscribers, committing to 50 lakh of the 66 lakh warrants. This fundraise is highly material, representing nearly 97% of the company's current market capitalization of ₹30 crore.
Confidence: HIGH
What changedThe company is initiating a massive capital infusion, primarily funded by promoters, at a price higher than the current market valuation.
Why it mattersA fundraise nearly equal to the company's market cap provides substantial liquidity to scale operations or reduce debt (currently ₹17 Cr), though it will lead to significant equity dilution upon conversion.
Total Fundraise Amount: ₹29.04 CrFundraise vs Market Cap: ~96.8%Issue Price: ₹44Upfront Payment (25%): ₹7.26 CrTotal Warrants: 66,00,000
📅 Short termThe announcement is likely to be viewed positively by the market due to the promoter participation and the issue price being at a premium to the current market price.
📈 Long termIf the capital is deployed effectively into high-margin pharmaceutical segments, it could structurally re-rate the company given its current low P/E of 7.6 and small scale.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Significant equity dilution (approx 43% of post-issue capital)
- 18-month window for full capital infusion
- Low operating margins (1.5%)
Key Highlights
Total fundraise of ₹29.04 crore through the issuance of 66,00,000 convertible warrants.
Issue price set at ₹44 per warrant, including a premium of ₹34 per share.
Promoters and promoter group to subscribe to 50,00,000 warrants, signaling strong internal confidence.
Authorized share capital increased from ₹8.5 crore to ₹15 crore to facilitate the issuance.
Warrants are convertible into equity shares at a 1:1 ratio within a period of 18 months.
👀 What to Watch
Investors should monitor the shareholder approval at the upcoming AGM on September 01, 2026, and look for management commentary on the specific utilization of these funds.
Chandra Bhagat Pharma to consider fundraise via preferential issue on August 5, 2026
Chandra Bhagat Pharma has scheduled a board meeting for August 5, 2026, to consider raising funds through a preferential allotment of equity shares or convertible warrants. This move comes as the company maintains a small market capitalization of Rs 26 Cr despite a significant TTM revenue of Rs 204 Cr. The board will also discuss increasing the authorized share capital to facilitate this issuance. The consideration for the issue may be in cash or 'other than cash', which often indicates potential asset acquisitions or debt-to-equity swaps.
Confidence: HIGH
What changedThe company is initiating a formal process to raise capital through a preferential issue, moving beyond its current capital structure.
Why it mattersFor a micro-cap company with a market cap of only Rs 26 Cr and debt of Rs 17 Cr, a sizeable fundraise could significantly impact liquidity, debt levels, and growth capacity, though it will likely result in equity dilution.
Market Cap: Rs 26 CrTTM Revenue: Rs 204 CrBoard Meeting Date: August 5, 2026Promoter Holding: 73.02%Debt-to-Equity Ratio: 0.50
📅 Short termThe stock may see increased volatility leading up to and immediately following the August 5 board meeting as details of the dilution and pricing are revealed.
📈 Long termThe long-term impact depends on whether the funds are used to scale operations or reduce debt, especially given the company's thin operating margins of 1.5%.
⚠ Risk flags
- Equity dilution for existing retail shareholders
- Potential for 'other than cash' consideration which requires scrutiny of asset valuation
- Micro-cap liquidity risks
Key Highlights
Board meeting scheduled for August 5, 2026, to approve preferential allotment.
Proposal includes issuance of equity shares, convertible warrants, or other instruments.
Trading window for insiders closed from July 30, 2026, until 48 hours post-meeting.
Company currently has a low market cap of Rs 26 Cr relative to TTM revenue of Rs 204 Cr.
Promoter holding has shown a steady increase from 69.29% in Sep 2024 to 73.02% in Mar 2026.
👀 What to Watch
Investors should monitor the post-meeting disclosure on August 5 for the specific fundraise amount, the issue price per share, and the identity of the proposed allottees.
